mavoglurant

08/01/2021 - "However, clinical trials showed inconsistent results regarding the efficacy of mavoglurant in treating LID in patients with Parkinson's disease (PD). "
08/01/2014 - "Mavoglurant as a treatment for Parkinson's disease."
01/01/2016 - "This study explored whether Parkinson's disease patients with L-dopa-induced dyskinesia experience improved OFF-time from higher L-dopa doses without worsening of dyskinesias when receiving adjunctive mavoglurant. "
01/01/2016 - "However, our results suggest that mavoglurant combined with higher doses of L-dopa may be effective in treating patients with Parkinson's disease experiencing L-dopa-related motor fluctuations and dyskinesias."
06/01/2011 - "Study objectives were to assess the efficacy, safety, and tolerability of AFQ056 in Parkinson's disease patients with levodopa-induced dyskinesia. "

01/01/2016 - "The Modified Abnormal Involuntary Movement Scale scores showed a slight improvement with mavoglurant compared with placebo, while the Unified Dyskinesia Rating Scale parts III and IV worsened slightly with mavoglurant compared with placebo. "
01/01/2016 - "Both studies failed to meet the primary objective of demonstrating improvement of dyskinesia with mavoglurant treatment. "
01/01/2016 - "Differences in least-squares mean (standard error) change in modified Abnormal Involuntary Movement Scale total score in week 12 did not reach statistical significance in either study (study 1: mavoglurant 100 mg twice a day versus placebo, 1.7 [1.31]; study 2: mavoglurant 150 mg twice a day (-1.3 [1.16]) and 200 mg twice a day (-0.2 [1.03]) versus placebo). "
08/01/2021 - "However, the pooled modified abnormal involuntary movement scale favored the mavoglurant group than the placebo group (MD -2.53, 95% CI -4.23 to -0.82). "
01/01/2016 - "ON-time without troublesome dyskinesia increased more from baseline to week 5 in the mavoglurant group (4.38 h) versus the placebo group (0.63 h). "

11/19/2018 - "Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents."
01/13/2016 - "Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials."
01/01/2016 - "Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study."
08/31/2023 - "Effects of AFQ056 on language learning in fragile X syndrome."
01/01/2019 - "Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome."

09/01/2014 - "Three randomized, double-blind clinical trials reported anti-dyskinetic efficacy of mavoglurant, without effects on anti-parkinsonian therapy, with dizziness the most common adverse event. "
11/01/2013 - "The most common adverse events (with incidence greater with AFQ056 than with placebo) were dizziness, hallucination, fatigue, nasopharyngitis, diarrhea, and insomnia. "

03/01/2015 - "A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease."
03/01/2015 - "This study investigated the hypothesis that AFQ056 (mavoglurant), a selective metabotropic glutamate receptor 5 antagonist, reduces chorea in Huntington's disease (HD). "